Complement activation is critical for placental ischemia-induced hypertension in the rat

Molecular Immunology

Volumn 56, Issue 1-2, 2013, Pages 91-97

  Lillegard, Kathryn E ^a   Johnson, Alex C ^a   Lojovich, Sarah J ^a   Bauer, Ashley J ^a   Marsh, Henry C ^b   Gilbert, Jeffrey S ^c   Regal, Jean F ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Celldex Therapeutics Inc   (United Kingdom)

^c UNIVERSITY OF OREGON   (United States)

Author keywords

C3a; Complement; Hypertension; Placental ischemia; Preeclampsia; Pregnancy; Vascular endothelial growth factor

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPERTENSION; MEAN ARTERIAL PRESSURE; MOUSE; MYOGRAPHY; NONHUMAN; PERFUSION PRESSURE; PLACENTA; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY;

ANIMALS; ARTERIAL PRESSURE; CAROTID ARTERIES; COMPLEMENT ACTIVATION; COMPLEMENT C3; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; ISCHEMIA; MALE; NITROPRUSSIDE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, COMPLEMENT; TIME FACTORS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASODILATION; VASODILATOR AGENTS;

EID: 84877891185     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.04.009     Document Type: Article

References (49)

1. Alexander B.T., Kassab S.E., Miller M.T., Abram S.R., Reckelhoff J.F., Bennett W.A., Granger J.P. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001, 37:1191-1195.
2. Baines M.G., Millar K.G., Mills P. Studies of complement levels in normal human pregnancy. Obstetrics and Gynecology 1974, 43:806-810.
3. Baker P.N., Krasnow J., Roberts J.M., Yeo K.T. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstetrics and Gynecology 1995, 86:815-821.
4. Balta O., Boztosun A., Deveci K., Gulturk S., Ekici F., Kaya A., Cetin A., Cetin M. Reduced uterine perfusion pressure model is not successful to mimic severe preeclampsia. Placenta 2011, 32:675-680.
5. Buhimschi I.A., Shi S.Q., Saade G.R., Garfield R.E. Marked variation in responses to long-term nitric oxide inhibition during pregnancy in outbred rats from two different colonies. American Journal of Obstetrics and Gynecology 2001, 184:686-693.
6. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013, 34:201-203.
7. Crews J.K., Herrington J.N., Granger J.P., Khalil R.A. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension 2000, 35:367-372.
8. Denny K.J., Woodruff T.M., Taylor S.M., Callaway L.K. Complement in pregnancy: a delicate balance. American Journal of Reproductive Immunology 2013, 69:3-11.
9. Derzsy Z., Prohaszka Z., Rigo J., Fust G., Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Molecular Immunology 2010, 47:1500-1506.
10. George E.M. Hypoxia-induced heparanase regulates sFlt-1 release from placental chorionic villi. Hypertension 2012, 60:A48.
11. Ghiran I., Barbashov S.F., Klickstein L.B., Tas S.W., Jensenius J.C., Nicholson-Weller A. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. Journal of Experimental Medicine 2000, 192:1797-1808.
12. Gilbert J., Dukes M., LaMarca B., Cockrell K., Babcock S., Granger J. Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. American Journal of Hypertension 2007, 20:686-691.
13. Gilbert J.S., Babcock S.A., Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007, 50:1142-1147.
14. Gilbert J.S., Bauer A.J., Gingery A., Banek C.T., Chasson S. Circulating and utero-placental adaptations to chronic placental ischemia in the rat. Placenta 2012, 33:100-105.
15. Gilbert J.S., Ryan M.J., LaMarca B.B., Sedeek M., Murphy S.R., Granger J.P. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. American Journal of Physiology - Heart and Circulatory Physiology 2008, 294:H541-H550.
16. Gilbert J.S., Verzwyvelt J., Colson D., Arany M., Karumanchi S.A., Granger J.P. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010, 55:380-385.
17. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C., Wetsel R.A., Lambris J.D., Holers V.M., Salmon J.E. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation 2003, 112:1644-1654.
18. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine 2004, 10:1222-1226.
19. Girardi G., Yarilin D., Thurman J.M., Holers V.M., Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. Journal of Experimental Medicine 2006, 203:2165-2175.
20. Goodfellow R.M., Williams A.S., Levin J.L., Williams B.D., Morgan B.P. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clinical and Experimental Immunology 1997, 110:45-52.
21. Gorsuch W.B., Chrysanthou E., Schwaeble W.J., Stahl G.L. The complement system in ischemia-reperfusion injuries. Immunobiology 2012, 217:1026-1033.
22. Granger J.P., LaMarca B.B., Cockrell K., Sedeek M., Balzi C., Chandler D., Bennett W. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods in Molecular Medicine 2006, 122:383-392.
23. Griffin K., Polichnowski A., Licea-Vargas H., Picken M., Long J., Williamson G., Bidani A. Large BP-dependent and -independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers. American Journal of Physiology. Renal Physiology 2012, 302:F173-F182.
24. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., Espinola R., Xiaowei L.E., Mao D., Vialpando C.G., Salmon J.E. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. Journal of Experimental Medicine 2002, 195:211-220.
25. Hubel C.A. Oxidative stress in the pathogenesis of preeclampsia. Proceedings of the Society for Experimental Biology and Medicine 1999, 222:222-235.
26. Keir L., Welsh G.I., Coward R.J., Satchell S., Saleem M.A., Richards A. VEGF-A regulates glomerular endothelial cell expression of protective complement regulators involved in the pathogenesis of atypical haemolytic uraemic syndrome. Immunobiology 2012, 217:1215.
27. Kelly R., Arnold L., Richards S., Hill A., Bomken C., Hanley J., Loughney A., Beauchamp J., Khursigara G., Rother R.P., Chalmers E., Fyfe A., Fitzsimons E., Nakamura R., Gaya A., Risitano A.M., Schubert J., Norfolk D., Simpson N., Hillmen P. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. British Journal of Haematology 2010, 149:446-450.
28. Klickstein L.B., Barbashov S.F., Liu T., Jack R.M., Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997, 7:345-355.
29. Larsen C.P., Regal R.R., Regal J.F. Trimellitic anhydride-induced allergic response in the guinea pig lung involves antibody-dependent and -independent complement system activation. Journal of Pharmacology and Experimental Therapeutics 2001, 296:284-292.
30. Li J., LaMarca B., Reckelhoff J.F. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. American Journal of Physiology - Heart and Circulatory Physiology 2012, 303:H1-H8.
31. Lynch A.M., Gibbs R.S., Murphy J.R., Giclas P.C., Salmon J.E., Holers V.M. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstetrics and Gynecology 2011, 117:75-83.
32. Lynch A.M., Salmon J.E. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010, 31:561-567.
33. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annual Review of Medicine 2008, 59:61-78.
34. Mistry H.D., Kurlak L.O., Broughton Pipkin F. The placental renin-angiotensin system and oxidative stress in pre-eclampsia. Placenta 2013, 34:182-186.
35. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. Journal of Immunology 1994, 152:5477-5484.
36. Pollock D.M., Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. The American Journal of Physiology 1998, 275:R1719-R1723.
37. Pratt J.R., Harmer A.W., Levin J., Sacks S.H. Influence of complement on the allospecific antibody response to a primary vascularized organ graft. European Journal of Immunology 1997, 27:2848-2853.
38. Proctor L.M., Moore T.A., Monk P.N., Sanderson S.D., Taylor S.M., Woodruff T.M. Complement factors C3a and C5a have distinct hemodynamic effects in the rat. International Immunopharmacology 2009, 9:800-806.
39. Qing X., Redecha P.B., Burmeister M.A., Tomlinson S., D'Agati V.D., Davisson R.L., Salmon J.E. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney International 2011, 79:331-339.
40. Regal J.F., Eastman A.Y., Pickering R.J. C5a induced tracheal contraction: a histamine independent mechanism. Journal of Immunology 1980, 124:2876-2878.
41. Regal J.F., Klos A. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 2000, 46:15-28.
42. Searle J., Mockel M., Gwosc S., Datwyler S.A., Qadri F., Albert G.I., Holert F., Isbruch A., Klug L., Muller D.N., Dechend R., Muller R., Vollert J.O., Slagman A., Mueller C., Herse F. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro - brief report. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:2972-2974.
43. Singh J., Ahmed A., Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011, 58:716-724.
44. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
45. Taktak Y.S., Stenning B. Solid phase enzyme immunoassays for the quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera. Hormone and Metabolic Research 1992, 24:371-374.
46. Usami M., Mitsunaga K., Miyajima A., Sunouchi M., Doi O. Complement component C3 functions as an embryotrophic factor in early postimplantation rat embryos. The International Journal of Developmental Biology 2010, 54:1277-1285.
47. Wang W., Irani R.A., Zhang Y., Ramin S.M., Blackwell S.C., Tao L., Kellems R.E., Xia Y. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012, 60:712-721.
48. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.
49. Zhou C.C., Zhang Y., Irani R.A., Zhang H., Mi T., Popek E.J., Hicks M.J., Ramin S.M., Kellems R.E., Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nature Medicine 2008, 14:855-862.